ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO530

Elevated Serum Gd-IgA1/s.IgA Levels and Not Serum Gd-IgA1 Alone Is an Independent Risk Factor for Composite Outcome in South Asian IgA Nephropathy (IgAN)

Session Information

Category: Glomerular Diseases

  • 1401 Glomerular Diseases: From Inflammation to Fibrosis


  • Alexander, Suceena, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Mani, Selvin Sundar Raj, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • Varughese, Santosh, Christian Medical College Vellore, Vellore, Tamil Nadu, India
  • John, George, Christian Medical College Vellore, Vellore, Tamil Nadu, India

Group or Team Name


The role of serum Gd-IgA1 in a prospective longitudinal South Asian IgAN cohort (GRACE-IgANI) and the impact of immunosuppression is not known.


We measured serum galactose-deficient IgA1 (s.Gd-IgA1) levels in 170 IgAN patients, 40 disease controls, and 27 healthy controls by KM55 ELISA (IBL international GmBH, Germany) at baseline. Longitudinal measurements were made at 1 year and 2 years in a subgroup of 117 IgAN patients who received a short course of immunosuppression. The baseline associations and the usefulness of s.Gd-IgA1 as a diagnostic and prognostic biomarker was assessed.


s.Gd-IgA1 had significant positive correlation with serum immunoglobulin A (s.IgA) (r=0.6, n=170, p<0.001). Neither s.Gd-IgA1 nor s.Gd-IgA1/s.IgA ratio was a diagnostic marker for IgAN. s.Gd-IgA1/s.IgA ratio had stronger baseline and longitudinal associations than s.Gd-IgA1 alone. Elevated s.Gd-IgA1/s.IgA ratio was significantly associated with baseline clinical and histopathological indices of activity and chronicity. In the subgroup that received immunosuppression, there was significant decrease in both s.Gd-IgA1 and s.IgA at 1 year . The mean time to the composite outcome was significantly shorter for each quartile increase in s.Gd-IgA1/s.IgA ratio by Kaplan-Meier survival analysis [<1.3: vs. 1.3-1.7 HR 3.3 (95% CI 1.2-9.1), 1.7-2.3 HR 4.3 (95% CI 1.6-11.9), >2.3 HR 6.2 (95% CI 2.4-16.2), p<0.001]. Higher median s.Gd-IgA1/s.IgA ratio was as an independent predictor for composite outcome by Cox proportional-hazards (HR 2.3, 95% C.I. 1.2-4.5, p=0.01) model and outperformed 24-hour urine protein.


We have shown for the first time in IgAN with South Asian ethnicity, the relevance of proportion of s.Gd-IgA1 to total serum IgA for risk stratification, its association with prognosis and its longitudinal changes with immunosuppression . The results need to be externally validated.


  • Government Support – Non-U.S.